SCHEMBL18779331

SCHEMBL18779331

Cc1cnc(CN2CCN(S(C)(=O)=O)CC2)nc1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 1/20 0.47
KDR P35968 2/20 0.46
KDM4E B2RXH2 1/20 0.43
ALOX15 P16050 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 3/20 0.43
RECQL P46063 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
LYN P07948 1/20 0.42
SRC P12931 1/20 0.42
ALDH1A1 P00352 3/20 0.41
PIK3CA P42336 2/20 0.41
HSD17B10 Q99714 1/20 0.40
PTGS2 P35354 1/20 0.40
PIK3CD O00329 1/20 0.39
PIK3R1 P27986 1/20 0.39
PIK3CB P42338 1/20 0.39
MTOR P42345 1/20 0.39
PIK3CG P48736 1/20 0.39
AKT1 P31749 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17111621 0.87 NTRK1 (0.46) NTRK1KDRKDM4EALOX15HTT
SCHEMBL17111593 0.85 NTRK1 (0.58) NTRK1KDRKDM4EALOX15HTT
SCHEMBL18779335 0.75 PTGS2 (0.40) NTRK1KDM4ESMN1; SMN2ALDH1A1HSD17B10
SCHEMBL18779326 0.74 NTRK1 (0.43) NTRK1KDM4ESMN1; SMN2ALDH1A1HSD17B10
SCHEMBL18779311 0.72 PDE10A (0.39) SMN1; SMN2ALDH1A1HSD17B10PTGS2ATM
SCHEMBL10271772 0.70 PDE10A (0.43) NTRK1KDRKDM4ENPSR1SMN1; SMN2
SCHEMBL1029651 0.70 RECQL (0.73) KDM4ERECQLSMN1; SMN2ALDH1A1MEN1
SCHEMBL6016324 0.70 CHRM5 (0.46) NTRK1KDM4ESMN1; SMN2ALDH1A1PTGS2
SCHEMBL18779308 0.69 NTRK1 (0.47) NTRK1ALDH1A1HSD17B10MEN1KMT2A
SCHEMBL18779309 0.69 PDE10A (0.42) NTRK1KDRKDM4EHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9815846-B2 TrkA kinase inhibitors, compositions and methods thereof MERCK SHARP & DOHME CORP. (US) 2017-11-14 US disclosed
US-20170114071-A1 TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF MERCK SHARP & DOHME CORP. (US) 2017-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170114071-A1 TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF NGFR, NGF, NTRK1 NTRK1 3/4885KDR 15/4885KDM4E 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.